+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

LAMA/LABA fixed dose combination for treatment of COPD

LAMA/LABA fixed dose combination for treatment of COPD

Nihon Rinsho. Japanese Journal of Clinical Medicine 74(5): 820-826

Several new fixed-dose combination bronchodilators have been launched in the world, and 3 different types are now available in Japan. Assessing their efficacy relative to each other has not been performed yet. In the present manuscript, characteristics of glycopyrronium/indacaterol, umeclidinium/vilanterol and tiotropium/olodaterol were reviewed. In particular, changes in trough and peak forced expiratory volume in 1 second (FEV1), St George's Respiratory Questionnaire (SGRQ) total scores, and transitional dyspnea index (TDI) focal scores were reviewed in these bronchodilators.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 058191171

Download citation: RISBibTeXText

PMID: 27254953

Related references

Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?. European Clinical Respiratory Journal 2:, 2015

UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD. Clinicoeconomics and Outcomes Research 8: 667-674, 2016

COPD: LAMA / LABA fixed combination more effective than separately. Praxis 105(3): 167-168, 2016

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. International Journal of Chronic Obstructive Pulmonary Disease 13: 3115-3130, 2018

A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD. Expert Opinion on PharmacoTherapy 18(17): 1833-1843, 2017

Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD. Expert Review of Respiratory Medicine 10(7): 767-780, 2016

A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opinion on Drug Safety 17(5): 509-517, 2018

LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. European Respiratory Review 26(143):, 2017

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 12: 907-922, 2017

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA. International Journal of Chronic Obstructive Pulmonary Disease 14: 531-546, 2019

Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 13: 3203-3231, 2018

Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects. Pulmonary Pharmacology and Therapeutics 53: 33-38, 2018

POINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? Yes. Chest 154(4): 746-748, 2018

LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. International Journal of Chronic Obstructive Pulmonary Disease 10: 1093-1102, 2015

Characteristics and health care resource use of subjects with COPD in the year before initiating LAMA monotherapy or LAMA+LABA combination therapy: A U.S. database study. Managed Care 27(5): 40-47, 2018